

## ASX RELEASE

### AGM In-Person Attendance Update

Wellington, NZ, 12<sup>th</sup> August 2020: [Volpara Health Technologies](#) ("Volpara," "the Group," or "the Company"; ASX: VHT), a medical technology company whose cancer screening software platform assists in the delivery of personalised patient care, announces an important update for shareholders planning to attend the Company's Annual General Meeting (**AGM**) on 19 August 2020 in-person.

As a result of the New Zealand government announcing overnight that the country will be going into various stages of COVID-19 lockdown, and the Company's view that the lockdown will not be eased from current levels before next week's AGM, the Company would like to highlight the following with regards to next week's AGM:

- Under COVID-19 alert levels 2-4, social distancing is a requirement. Due to these requirements and the space allocated for the AGM at the Company's offices, any person wishing to attend the AGM in-person must now pre-register by emailing the Company Secretary, Craig Hadfield at [craig.hadfield@volparasolutions.com](mailto:craig.hadfield@volparasolutions.com). Regrettably, the Company cannot guarantee that any person who does not pre-register to attend in-person will be able to be admitted to the meeting on the day as a result of the likelihood of the lockdown remaining in place, and the associated requirement to adhere to the social distancing rules. Shareholders not able to attend in person will be able to view the proceedings by webcast (details below).
- In the circumstances, it is highly recommended that all shareholders submit their vote on each of the resolutions via proxy by no later than 12pm (New Zealand time) on 17 August 2020 to be valid for the AGM. This year all resolutions are being conducted by way of a poll so all proxy votes will count towards each poll.

As a reminder, for shareholders who are not able to attend the AGM in person, the webcast will now take place via Zoom. Shareholders who wish to view the proceedings on the webcast can do so at the following webcast [link](#).

**ENDS.**

### Authorisation and additional Information

This announcement was authorised by the CEO, Dr Ralph Highnam.

### For further information, please contact:

Ralph Highnam, CEO  
Volpara Health Technologies  
[ralph.highnam@volparasolutions.com](mailto:ralph.highnam@volparasolutions.com)  
t: +64 21 149 0541

Trevor Chappell  
WE Communications  
[WE-AUVolpara@we-worldwide.com](mailto:WE-AUVolpara@we-worldwide.com)  
t: +61 407 933 437

## **About Volpara Health Technologies Limited (ASX: VHT)**

VHT is a MedTech SaaS company founded in 2009 on research originally conducted at Oxford University. VHT's clinical functions for screening clinics provide feedback on breast density, compression, dose, and quality, while its enterprise-wide practice software management helps with productivity, compliance, reimbursement, and patient tracking.

VHT's technology and services have been used by customers and/or research projects in 38 countries and are supported by numerous patents, trademarks, and regulatory clearances, including FDA clearance and CE marking. Since its listing on the ASX in April 2016, VHT has raised A\$132 million, including A\$37 million in April/May 2020. VHT is based in Wellington, New Zealand.

At the end of June 2019, VHT acquired MRS Systems, Inc., a company based in Seattle, WA. MRS provides mammography reporting systems to over 1,600 breast clinics and hospitals, and to VHT a much stronger US presence, experienced local headquarters, and accelerated sales through cross-selling opportunities.

For more information, visit [www.volparasolutions.com](http://www.volparasolutions.com)